Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2006

View Archived Issues

AstraZeneca completes Cambridge Antibody Technology acquisition

SPA for second pivotal study of TH-9507 in HIV-associated lipodystrophy

Negative outcomes for first phase III study of Corlux in psychotic major depression

CUV-1647 meets endpoints in polymorphous light eruption study

Probactrix studied for dietary management of GERD

Enrollment completed in study of Ketasyn for age associated memory impairment

Devgen compounds may show promise for rheumatoid arthritis

LCT seeks approval to begin phase I/II diabetes study of DiabeCell in patients

ChronVac-C with Medpulser DDS shows good immune response in rabbits

Switch Pharma to acquire Gardant

Biotransformation of a novel delta/mu opioid receptor agonist with promising analgesic potential

New therapeutic agents for psoriasis disclosed in recent Nippon Shinyaku patent

Lilly reports on a novel class of positive allosteric modulators of AMPA receptors

AzaSite NDA accepted for review

Orapred ODT launched in U.S.

FDA denies Epix's formal appeal for Vasovist

First European approval for Lucentis in Switzerland

Apnecut launched in Japan for apnea of prematurity

Rotigotine transdermal patch enables rapid titration in Parkinson's disease patients

Novel agents for urological disorders disclosed in recent Dainippon Sumitomo patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
UK Biobank delivers largest metabolomics dataset of 500K profiles
BioWorld Science
It’s the biological resource that keeps on giving, and now UK Biobank has released the final tranche of data on the levels of 249 metabolites in the blood of its...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...